See more : Hunan Mendale Hometextile Co.,Ltd (002397.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Cara Therapeutics, Inc. (CARA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cara Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hitech Corporation Limited (HITECHCORP.BO) Income Statement Analysis – Financial Results
- Flutter Entertainment plc (FLTR.IR) Income Statement Analysis – Financial Results
- Coyni, Inc. (LOGQ) Income Statement Analysis – Financial Results
- IMV Inc. (IMVIF) Income Statement Analysis – Financial Results
- Live Oak Crestview Climate Acquisition Corp. (LOCC-WT) Income Statement Analysis – Financial Results
Cara Therapeutics, Inc. (CARA)
About Cara Therapeutics, Inc.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.97M | 41.87M | 23.03M | 135.08M | 19.89M | 13.47M | 911.00K | 86.00K | 3.80M | 3.18M | 11.96M | 1.19M | 0.00 |
| Cost of Revenue | 6.17M | 7.27M | 1.55M | 107.07M | 113.16M | 75.53M | 48.52M | 49.25M | 21.22M | 15.07M | 8.69M | 1.92M | 0.00 |
| Gross Profit | 14.79M | 34.60M | 21.47M | 28.01M | -93.28M | -62.06M | -47.61M | -49.17M | -17.42M | -11.89M | 3.28M | -731.00K | 0.00 |
| Gross Profit Ratio | 70.56% | 82.65% | 93.25% | 20.74% | -469.06% | -460.78% | -5,226.45% | -57,170.93% | -458.01% | -374.28% | 27.41% | -61.43% | 0.00% |
| Research & Development | 108.51M | 91.88M | 82.70M | 107.85M | 113.82M | 75.53M | 48.52M | 49.25M | 21.22M | 15.07M | 8.69M | 4.60M | 7.16M |
| General & Administrative | 27.65M | 30.26M | 29.41M | 21.75M | 17.75M | 15.32M | 11.87M | 9.23M | 7.77M | 6.18M | 3.52M | 2.83M | 2.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.65M | 30.26M | 29.41M | 21.75M | 17.75M | 15.32M | 11.87M | 9.23M | 7.77M | 6.18M | 3.52M | 2.83M | 2.41M |
| Other Expenses | 0.00 | 2.06M | 642.00K | 97.00K | 4.49M | 2.98M | 1.16M | 652.00K | 101.00K | 361.00K | 0.00 | 0.00 | -180.00K |
| Operating Expenses | 136.29M | 122.14M | 112.11M | 129.70M | 131.57M | 90.85M | 60.40M | 58.49M | 28.99M | 21.25M | 12.20M | 7.43M | 9.57M |
| Cost & Expenses | 142.46M | 129.40M | 112.11M | 129.70M | 131.57M | 90.85M | 60.40M | 58.49M | 28.99M | 21.25M | 12.20M | 7.43M | 9.57M |
| Interest Income | 0.00 | 2.06M | 603.00K | 2.06M | 4.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 604.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 126.00K | 3.76M | 0.00 | 0.00 |
| Depreciation & Amortization | 259.00K | 1.67M | 1.55M | 1.01M | 799.00K | 370.00K | 495.00K | 1.47M | 839.00K | 783.00K | 789.00K | 1.02M | 1.17M |
| EBITDA | -117.65M | -83.80M | -88.19M | 5.59M | -111.48M | -77.01M | -58.99M | -56.94M | -24.35M | -17.29M | 552.00K | -5.22M | -8.58M |
| EBITDA Ratio | -561.09% | -209.08% | -386.85% | 4.14% | -561.60% | -574.52% | -6,529.64% | -67,906.98% | -662.32% | -568.84% | -1.98% | -438.24% | 0.00% |
| Operating Income | -121.50M | -87.54M | -89.08M | 5.39M | -111.68M | -77.38M | -59.49M | -58.40M | -25.19M | -18.07M | -237.00K | -6.24M | -9.57M |
| Operating Income Ratio | -579.43% | -209.08% | -386.85% | 3.99% | -561.60% | -574.52% | -6,529.64% | -67,906.98% | -662.32% | -568.84% | -1.98% | -524.03% | 0.00% |
| Total Other Income/Expenses | 2.98M | 2.06M | 642.00K | 2.33M | 4.49M | 2.98M | 1.16M | 652.00K | 101.00K | 126.00K | -3.76M | -66.00K | -275.00K |
| Income Before Tax | -118.51M | -85.47M | -88.44M | 7.72M | -107.19M | -74.40M | -58.33M | -57.75M | -25.09M | -17.95M | -3.99M | -6.30M | -9.84M |
| Income Before Tax Ratio | -565.21% | -204.16% | -384.06% | 5.71% | -539.02% | -552.39% | -6,402.74% | -67,148.84% | -659.66% | -564.87% | -33.38% | -529.58% | 0.00% |
| Income Tax Expense | 0.00 | -2.06M | -248.00K | -691.00K | -816.00K | -389.00K | -204.00K | -468.00K | -397.00K | -201.00K | -30.00K | -31.00K | -35.00K |
| Net Income | -118.51M | -83.41M | -88.19M | 8.41M | -106.37M | -74.01M | -58.13M | -57.28M | -24.69M | -17.75M | -3.96M | -6.27M | -9.81M |
| Net Income Ratio | -565.21% | -199.23% | -382.98% | 6.23% | -534.91% | -549.51% | -6,380.35% | -66,604.65% | -649.22% | -558.55% | -33.12% | -526.97% | 0.00% |
| EPS | -2.19 | -1.55 | -1.74 | 0.18 | -2.49 | -2.06 | -1.86 | -2.10 | -1.00 | -0.85 | -0.18 | -1.01 | -1.59 |
| EPS Diluted | -2.19 | -1.55 | -1.74 | 0.18 | -2.49 | -2.06 | -1.86 | -2.10 | -1.00 | -0.85 | -0.18 | -1.01 | -1.59 |
| Weighted Avg Shares Out | 54.15M | 53.65M | 50.72M | 47.41M | 42.67M | 35.89M | 31.20M | 27.28M | 24.62M | 20.88M | 21.84M | 6.18M | 6.18M |
| Weighted Avg Shares Out (Dil) | 54.15M | 53.65M | 50.72M | 47.92M | 42.67M | 35.89M | 31.20M | 27.28M | 24.62M | 20.97M | 21.84M | 6.18M | 6.18M |
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
Why Is Cara Therapeutics (CARA) Stock Down 27% Today?
Cara Therapeutics discontinues study on a neurological condition as drug fails
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
Cara Therapeutics Reports First Quarter 2024 Financial Results
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
Cara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare Conference
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
Source: https://incomestatements.info
Category: Stock Reports